Skip to content
PubMed This is a summary of 10 peer-reviewed journal articles Updated
Pediatric Neurology · BCAP31-Related Deafness-Dystonia-Cerebral Hypomyelination Syndrome

Coordinating Care: Symptom-Directed Treatments and Your Child's Team

At a Glance

BCAP31-related DDCH has no single standard treatment plan or cure. A coordinated team tailors care for involuntary muscle stiffness, hearing loss, feeding and growth problems, and liver changes while supporting the child’s comfort, communication, mobility, and quality of life.

While there is currently no cure for BCAP31-related syndrome (DDCH), a well-coordinated team of specialists can significantly improve your child’s comfort, communication, and quality of life. Because this condition is so rare, there is no single “standard” treatment manual; instead, care is symptom-directed, meaning it is tailored to your child’s specific needs as they change over time [1][2].

Building Your Multidisciplinary Care Team

Managing DDCH requires a “village” of medical professionals. A typical care team includes:

  • Pediatric Neurologist: Often the lead specialist, they manage the movement disorder (dystonia), monitor for seizures, and track brain development [1][3].
  • Audiologist & ENT: These specialists monitor hearing levels and evaluate whether technologies like hearing aids or cochlear implants are appropriate [1][4].
  • Geneticist: They provide the formal diagnosis and help the family understand the inheritance pattern and risks for future children [2][4].
  • Gastroenterologist (GI) & Pulmonologist: Because many children have feeding difficulties, liver issues, or respiratory vulnerability, these doctors monitor organ health and ensure proper nutrition [2][5].
  • Therapy Team: Physical (PT), Occupational (OT), and Speech-Language (SLP) therapists are essential for supporting mobility and communication, starting from diagnosis [5].

Possible Symptom-Directed Treatments for Dystonia

Dystonia—involuntary muscle twisting and stiffness—can be one of the most challenging symptoms to manage. The goal of treatment is not to eliminate all movements, but to maximize comfort and function.

  • Medications: Doctors may trial various oral medications extrapolated from other pediatric movement disorders, such as baclofen, benzodiazepines, or anticholinergics. It is important to know that these can cause significant side effects, including sedation, worsened hypotonia, respiratory depression, and swallowing difficulty. Medication decisions require a pediatric movement-disorder clinician [6].
  • Focal Treatments: For stiffness in specific muscle groups, injections of botulinum toxin (Botox) are sometimes used to temporarily relax those muscles, bearing in mind risks of focal weakness or dysphagia [7].
  • Physical Therapy: Regular PT focuses on preventing contractures (permanent shortening of muscles or tendons) and helping your child find comfortable positions for sitting and sleeping [2].

Hearing Rehabilitation and Communication

Since sensorineural hearing loss is a core feature of DDCH, early intervention is vital.

  • Hearing Technologies: Some children benefit from high-powered hearing aids. In selected cases of profound hearing loss, cochlear implants have been used [1]. Candidacy for implants must be carefully evaluated by your team, as syndrome-specific outcome data is limited [8][9].
  • Alternative Communication (AAC): Many families find success using Total Communication, which combines any residual hearing with sign language, gestures, and Augmentative and Alternative Communication (AAC) devices (like picture boards or tablets) to help their child express their needs.

Liver and Growth Monitoring

Because liver enzyme elevations (AST and ALT) are reported in some individuals, your child will likely need regular blood work to ensure their liver remains stable [2]. If your child has a “contiguous gene deletion” (CADDS), this monitoring becomes even more critical, as the risk for severe liver issues is higher [10].

Additionally, because many children face feeding challenges or “failure to thrive,” a nutritionist or feeding specialist can help adjust their diet or recommend specialized feeding equipment if necessary [5]. Focusing on these “baseline” health factors gives your child the best foundation for their development.

Common questions in this guide

Who typically coordinates care for a child with BCAP31-related DDCH?
Care often includes a pediatric neurologist, audiologist and ear, nose, and throat specialist, geneticist, gastroenterologist, pulmonologist, and physical, occupational, and speech-language therapists. A pediatric neurologist may lead coordination, but your family and clinicians can decide who is the main point of contact. The team should revisit the plan as symptoms and goals change.
What options are used to manage dystonia in DDCH?
DDCH dystonia is treated according to the child’s comfort and function rather than by one fixed protocol. Options may include medicines such as baclofen, benzodiazepines, or anticholinergics, botulinum toxin injections for selected muscles, and physical therapy. A pediatric movement-disorder clinician should guide treatment because medicines can cause sleepiness, slowed breathing, weakness, or swallowing problems.
When might hearing aids or a cochlear implant be considered?
Some children with severe hearing loss benefit from hearing aids, and cochlear implants have been used in selected children with profound loss. An audiology and ear, nose, and throat team should assess candidacy and likely benefit because DDCH-specific outcome data are limited. Communication can also combine residual hearing with sign language, gestures, picture boards, or tablets.
How are liver health, nutrition, and growth followed in DDCH?
Regular blood tests can monitor liver enzymes called AST and ALT, while clinicians follow feeding, nutrition, and growth. Children with a contiguous gene deletion called CADDS may need especially careful liver monitoring because severe liver problems are more likely. The care team should decide how often testing is needed and when to involve a liver specialist.
How can therapy and communication tools help my child function?
Physical therapy can help prevent permanent muscle shortening and support comfortable sitting and sleeping, while occupational therapy supports daily function. Speech-language therapy, sign language, gestures, and augmentative and alternative communication devices can help a child express needs. Goals can be based on comfort, mobility, and interaction with family.
How can our family track symptoms and manage caregiver stress?
A journal or app can record dystonia, sleep, pain, feeding, and communication changes, along with what seems to improve or worsen symptoms. Sharing these patterns can help the care team adjust treatment. Caregivers should also ask the team what practical and emotional support is available to reduce burnout.

Get notified when new evidence is published on Developmental malformations-deafness-dystonia syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (10)
  1. 1

    Case Report: The first Korean familial case of BCAP31-related deafness, dystonia, and cerebral hypomyelination.

    Suh YA, Hwang J, Seo GH, et al.

    Frontiers in pediatrics 2024; (12()):1488095 doi:10.3389/fped.2024.1488095.

    PMID: 39911770
  2. 2

    Further delineation of BCAP31-linked intellectual disability: description of 17 new families with LoF and missense variants.

    Whalen S, Shaw M, Mignot C, et al.

    European journal of human genetics : EJHG 2021; (29(9)):1405-1417 doi:10.1038/s41431-021-00821-0.

    PMID: 33603160
  3. 3

    BCAP31-associated encephalopathy and complex movement disorder mimicking mitochondrial encephalopathy.

    Albanyan S, Al Teneiji A, Monfared N, Mercimek-Mahmutoglu S

    American journal of medical genetics. Part A 2017; (173(6)):1640-1643 doi:10.1002/ajmg.a.38127.

    PMID: 28332767
  4. 4

    BCAP31-related syndrome: The first de novo report.

    Rinaldi B, Van Hoof E, Corveleyn A, et al.

    European journal of medical genetics 2020; (63(2)):103732 doi:10.1016/j.ejmg.2019.103732.

    PMID: 31330203
  5. 5

    Whole exome sequencing reveals a dual diagnosis of BCAP31-related syndrome and glutaric aciduria III.

    Huggins E, Jackson DG, Young SP, Kishnani PS

    Molecular genetics and metabolism reports 2024; (40()):101117 doi:10.1016/j.ymgmr.2024.101117.

    PMID: 39101156
  6. 6

    Long-Term Follow-Up with Video of a Patient with Deafness-Dystonia Syndrome Treated with DBS-GPi.

    Dulski J, Schinwelski M, Mandat T, et al.

    Stereotactic and functional neurosurgery 2016; (94(2)):123-5 doi:10.1159/000445078.

    PMID: 27100856
  7. 7

    Bilateral Globus Pallidus Internus Deep Brain Stimulation in a Case of Progressive Dystonia in Mohr-Tranebjaerg Syndrome with Bilateral Cochlear Implants.

    Coenen VA, Rijntjes M, Sajonz B, et al.

    Journal of neurological surgery. Part A, Central European neurosurgery 2019; (80(1)):44-48 doi:10.1055/s-0038-1669472.

    PMID: 30290379
  8. 8

    Cochlear Implantation Outcomes in Post Synaptic Auditory Neuropathies: A Systematic Review and Narrative Synthesis.

    Chaudhry D, Chaudhry A, Muzaffar J, et al.

    The journal of international advanced otology 2020; (16(3)):411-431 doi:10.5152/iao.2020.9035.

    PMID: 33136025
  9. 9

    Progressive deafness-dystonia due to SERAC1 mutations: A study of 67 cases.

    Maas RR, Iwanicka-Pronicka K, Kalkan Ucar S, et al.

    Annals of neurology 2017; (82(6)):1004-1015 doi:10.1002/ana.25110.

    PMID: 29205472
  10. 10

    Interstitial lung disease and pancreatic exocrine insufficiency in CADDS: Phenotypic expansion and literature review.

    Heath O, Pandithan D, Pitt J, et al.

    JIMD reports 2023; (64(5)):337-345 doi:10.1002/jmd2.12390.

    PMID: 37701323

This page is for informational purposes only and does not constitute medical advice. A pediatric movement-disorder clinician and your child’s multidisciplinary team should guide medication, hearing, therapy, nutrition, and liver-monitoring decisions.